WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H581085
CAS#: 257892-34-5
Description: D-4418, is PDE4 inhibitors has been in development as a novel anti-inflammatory therapy with asthma and chronic obstructive pulmonary disease (COPD) being primary indications.
Hodoodo Cat#: H581085
Name: D-4418
CAS#: 257892-34-5
Chemical Formula: C16H11Cl2N3O2
Exact Mass: 347.02
Molecular Weight: 348.180
Elemental Analysis: C, 55.19; H, 3.18; Cl, 20.36; N, 12.07; O, 9.19
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: D-4418; D4418; UNII-24A61J8R9E;
IUPAC/Chemical Name: 5-Quinolinecarboxamide, N-(2,5-dichloro-3-pyridinyl)-8-methoxy-
InChi Key: FSDOTMQXIKBFKJ-UHFFFAOYSA-N
InChi Code: InChI=1S/C16H11Cl2N3O2/c1-23-13-5-4-11(10-3-2-6-19-14(10)13)16(22)21-12-7-9(17)8-20-15(12)18/h2-8H,1H3,(H,21,22)
SMILES Code: O=C(C1=C2C=CC=NC2=C(OC)C=C1)NC3=CC(Cl)=CN=C3Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 348.18 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Crocker IC, Townley RG. Therapeutic potential of phosphodiesterase 4 inhibitors in allergic diseases. Drugs Today (Barc). 1999 Jul;35(7):519-35. PubMed PMID: 12973397.
2: Giembycz MA. Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? Br J Pharmacol. 2008 Oct;155(3):288-90. doi: 10.1038/bjp.2008.297. Epub 2008 Jul 28. PubMed PMID: 18660832; PubMed Central PMCID: PMC2567889.